Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment.
2003 · Endocrine Related Cancer · 334 citations
https://doi.org/10.1677/erc.0.0100001
A
Antonella De Luca
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
160
Papers
8.7K
Citations
42
h-index
81
i10-index
Antonella De Luca is an academic researcher from Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale". The author has contributed to research in topics: Lung Cancer Treatments and Mutations & HER2/EGFR in Cancer Research & Cancer Genomics and Diagnostics. The author has an h-index of 42, co-authored 136 publications.
ORCID: 0000-0001-5762-447XPapers by this author
worksMechanisms of endocrine resistance and novel therapeutic strategies in breast cancer
2005 · Endocrine Related Cancer · 285 citations
https://doi.org/10.1677/erc.1.00857
Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth
2002 · Annals of Oncology · 270 citations
https://doi.org/10.1093/annonc/mdf020
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs): Simple drugs with a complex mechanism of action?
2002 · Journal of Cellular Physiology · 145 citations
https://doi.org/10.1002/jcp.10194
Molecular diagnostics and personalized medicine in oncology: Challenges and opportunities
2012 · Journal of Cellular Biochemistry · 69 citations
https://doi.org/10.1002/jcb.24401
Breast cancer cells with acquired resistance to the EGFR tyrosine kinase inhibitor gefitinib show persistent activation of MAPK signaling
2007 · Breast Cancer Research and Treatment · 51 citations
https://doi.org/10.1007/s10549-007-9830-2
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat